Therapy for Hepatobiliary Cancers

Nov 10 2025
Convention Center: Ballroom C, Level 3
11:00 AM - 12:30 PM

World Class Speakers

Ajay K. Duseja, MD, DM, FAASLD, FACG, FAMS, FINASL, Master-ISG
Abstract Presenter

Ajay K. Duseja, MD, DM, FAASLD, FACG, FAMS, FINASL, Master-ISG

Postgraduate Institute of Medical Education & Research
Andrew Moon, MD, MPH
Abstract Presenter

Andrew Moon, MD, MPH

University of North Carolina
Kara Wegermann, MD
Abstract Presenter

Kara Wegermann, MD

Duke University
Andrew Moon, MD, MPH
Moderator

Andrew Moon, MD, MPH

University of North Carolina
Kara Wegermann, MD
Moderator

Kara Wegermann, MD

Duke University

Description

The therapeutic options for patients with hepatobiliary cancers are expanding, and at the same time the impact of comorbidities on outcomes has become clearer.  Participants will learn about the influence of  MASLD, tumor buden and liver heatlh on treatment success; the potential of immuotherapy in HCC; and consider surgical treatment options in hepatobiliary cancers.

Journey Maps

Presentations

11:00 AM - 11:15 AM
May 19 2026
Washington, D.C.

Impact of hepatic steatosis and metabolic dysfunction on disease severity and treatment outcomes in patients with hepatocellular carcinoma

Ajay K. Duseja, MD, DM, FAASLD, FACG, FAMS, FINASL, Master-ISG , Abstract Presenter
Liver Cancer
11:15 AM - 11:30 AM
May 19 2026
Washington, D.C.

Living Donor Liver Transplantation Remains Underutilized for Cholangiocarcinoma Despite Comparable Survival

Andrew Moon, MD, MPH , Abstract Presenter
Liver Cancer
11:45 AM - 12:00 PM
May 19 2026
Washington, D.C.

Molecular-based therapies for primary liver cancers: real-world data from 120 patients of the 2025 French Genomic Medicine Initiative

Kara Wegermann, MD , Abstract Presenter
Liver Cancer

Objectives

  • Describe the role of comorbid influences such as MASLD or liver health on treatment of HCC.
  • Evaluate immunologic, radiologic and surgical therapies for hepato-biliary cancers.